-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 9, the domestic retail chain pharmacy giant Dashenlin Pharmaceutical Group Co.
, Ltd.
(hereinafter referred to as Dashenlin) increased its foreign investment.
There are 2 investment companies, one is Hebei Jibao Pharmaceutical Technology Co.
, Ltd.
, with an investment ratio of 90 %; The other is Dashenlin Taihua (Suihua) Pharmaceutical Chain Co.
, Ltd.
, with an investment ratio of 46.
62%
.
According to data, Hebei Jibao Pharmaceutical Technology Co.
, Ltd.
was established on May 15, 2020, with a registered capital of 3 million yuan.
Its business scope includes wholesale and retail of Chinese patent medicines, chemical preparations, and antibiotic preparations
.
The company’s current shareholders have changed.
Wang Yingjie, Yuan Jun, and Rong Haiyan withdrew, holding 80%, 10%, and 10% of the shares respectively before exiting.
Dashenlin and Guangdong Dashenlin Bokang Chain Drugstore Co.
, Ltd.
were newly added, holding 90% and 10% of shares respectively.
%
.
At the same time, the type of enterprise has also changed, from "limited liability company (natural person investment or holding)" to "other limited liability company"
.
Dashenlin Taihua (Suihua) Pharmaceutical Chain Co.
, Ltd.
was established on January 17, 2002, with a registered capital of 5.
445 million yuan.
Its business scope includes drug retailing; third-class medical device management; Chinese herbal medicine decoction on behalf of decoction services
.
Dashenlin became the major shareholder of the company, holding approximately 46.
62% of the shares
.
Through foreign investment, it is conducive to enterprises to solve the problem of insufficient supply of certain resources in production and operation, and to improve the efficiency of capital use
.
In addition, the use of holding investment methods can enable enterprises to achieve the purpose of enterprise expansion with less funds
.
Since 2021, Dashenlin's foreign investment has been on the rise, and in September alone, the company has increased its foreign investment many times
.
For example, on September 27, Dashenlin increased its foreign investment.
The newly-added investment company was Deyang Dacheng Family Health Chain Pharmacy Co.
, Ltd.
, which was established on October 9, 2015 with a registered capital of 7 million yuan
.
The company's business scope covers the sales of medicines, medical devices, and health care products
.
The investment ratio of Dashenlin is 51%
.
On September 24, according to the company's investigation, Dashenlin increased its foreign investment.
The newly-increased investment company was Heilongjiang Dashenlin Pharmaceutical Co.
, Ltd.
, which was established on September 16, 2021 with a registered capital of 10 million yuan
.
The company's business scope covers the wholesale of medicines and the operation of the third-class medical equipment
.
On September 10, the company's investigation revealed that Dashenlin had increased its foreign investment.
The investment company was Weishan County Runkang Plaza Pharmaceutical Chain Co.
, Ltd.
, with an investment ratio of 51%
.
Yun Kang Square pharmaceutical chain was founded in 2012, February 9, the registered capital of 6 million yuan, business scope, including Chinese Herbal Medicine, Chinese medicine, antibiotic preparations
.
According to incomplete statistics, Dashenlin currently has more than 100 foreign investment companies.
The industries of the investment companies mainly include wholesale and retail, manufacturing, scientific research, and technical services
.
Dashenlin is a pharmaceutical manufacturing, retail, wholesale as one of the group of enterprises, the main business scope includes the wholesale of Chinese herbal medicines (acquisition), Chinese Herbal Medicine, Chinese medicine and so on
.
In recent years, the reshuffle of the pharmaceutical retail market has become a general trend, and the industry concentration is increasing, forcing enterprises to transform and upgrade.
A number of small and medium pharmacies will be eliminated or merged and reorganized at an accelerated pace, and the market share of chain giants is expected to further increase
.
Looking back this year, domestic retail chain pharmacies, including Yixintang, Yifeng Pharmacy, Dashenlin, and ordinary people, are all speeding up the race
.
In terms of the number of stores, as of September 30, 2021, Dashenlin has 7610 stores, and the company has a net increase of 1,590 stores, including 829 new stores, 416 acquired stores, 423 franchise stores, and 78 closed stores.
Home
.
Among the four major chain giants, Dashenlin's number of stores ranks third
.
Judging from the revenue of Dashenlin, in the first three quarters, the company achieved operating income of 12.
355 billion yuan, a year-on-year increase of 17.
75%; net profit attributable to the parent company was 818 million yuan, a year-on-year decrease of 5.
62%
.
, Ltd.
(hereinafter referred to as Dashenlin) increased its foreign investment.
There are 2 investment companies, one is Hebei Jibao Pharmaceutical Technology Co.
, Ltd.
, with an investment ratio of 90 %; The other is Dashenlin Taihua (Suihua) Pharmaceutical Chain Co.
, Ltd.
, with an investment ratio of 46.
62%
.
According to data, Hebei Jibao Pharmaceutical Technology Co.
, Ltd.
was established on May 15, 2020, with a registered capital of 3 million yuan.
Its business scope includes wholesale and retail of Chinese patent medicines, chemical preparations, and antibiotic preparations
.
The company’s current shareholders have changed.
Wang Yingjie, Yuan Jun, and Rong Haiyan withdrew, holding 80%, 10%, and 10% of the shares respectively before exiting.
Dashenlin and Guangdong Dashenlin Bokang Chain Drugstore Co.
, Ltd.
were newly added, holding 90% and 10% of shares respectively.
%
.
At the same time, the type of enterprise has also changed, from "limited liability company (natural person investment or holding)" to "other limited liability company"
.
Dashenlin Taihua (Suihua) Pharmaceutical Chain Co.
, Ltd.
was established on January 17, 2002, with a registered capital of 5.
445 million yuan.
Its business scope includes drug retailing; third-class medical device management; Chinese herbal medicine decoction on behalf of decoction services
.
Dashenlin became the major shareholder of the company, holding approximately 46.
62% of the shares
.
Through foreign investment, it is conducive to enterprises to solve the problem of insufficient supply of certain resources in production and operation, and to improve the efficiency of capital use
.
In addition, the use of holding investment methods can enable enterprises to achieve the purpose of enterprise expansion with less funds
.
Since 2021, Dashenlin's foreign investment has been on the rise, and in September alone, the company has increased its foreign investment many times
.
For example, on September 27, Dashenlin increased its foreign investment.
The newly-added investment company was Deyang Dacheng Family Health Chain Pharmacy Co.
, Ltd.
, which was established on October 9, 2015 with a registered capital of 7 million yuan
.
The company's business scope covers the sales of medicines, medical devices, and health care products
.
The investment ratio of Dashenlin is 51%
.
On September 24, according to the company's investigation, Dashenlin increased its foreign investment.
The newly-increased investment company was Heilongjiang Dashenlin Pharmaceutical Co.
, Ltd.
, which was established on September 16, 2021 with a registered capital of 10 million yuan
.
The company's business scope covers the wholesale of medicines and the operation of the third-class medical equipment
.
On September 10, the company's investigation revealed that Dashenlin had increased its foreign investment.
The investment company was Weishan County Runkang Plaza Pharmaceutical Chain Co.
, Ltd.
, with an investment ratio of 51%
.
Yun Kang Square pharmaceutical chain was founded in 2012, February 9, the registered capital of 6 million yuan, business scope, including Chinese Herbal Medicine, Chinese medicine, antibiotic preparations
.
According to incomplete statistics, Dashenlin currently has more than 100 foreign investment companies.
The industries of the investment companies mainly include wholesale and retail, manufacturing, scientific research, and technical services
.
Dashenlin is a pharmaceutical manufacturing, retail, wholesale as one of the group of enterprises, the main business scope includes the wholesale of Chinese herbal medicines (acquisition), Chinese Herbal Medicine, Chinese medicine and so on
.
In recent years, the reshuffle of the pharmaceutical retail market has become a general trend, and the industry concentration is increasing, forcing enterprises to transform and upgrade.
A number of small and medium pharmacies will be eliminated or merged and reorganized at an accelerated pace, and the market share of chain giants is expected to further increase
.
Looking back this year, domestic retail chain pharmacies, including Yixintang, Yifeng Pharmacy, Dashenlin, and ordinary people, are all speeding up the race
.
In terms of the number of stores, as of September 30, 2021, Dashenlin has 7610 stores, and the company has a net increase of 1,590 stores, including 829 new stores, 416 acquired stores, 423 franchise stores, and 78 closed stores.
Home
.
Among the four major chain giants, Dashenlin's number of stores ranks third
.
Judging from the revenue of Dashenlin, in the first three quarters, the company achieved operating income of 12.
355 billion yuan, a year-on-year increase of 17.
75%; net profit attributable to the parent company was 818 million yuan, a year-on-year decrease of 5.
62%
.
